ClinicalTrials.gg
RecruitingNCT07671729Updated Jun 26, 2026

Quadriceps Tendon vs Peroneus Longus Tendon in ACL Reconstruction

An interventional study of Anterior Cruciate Ligament Reconstruction Using Quadriceps Tendon Autograft and Anterior Cruciate Ligament Reconstruction Using Peroneus Longus Tendon Autograft in Anterior Cruciate Ligament Injury and Anterior Cruciate Ligament Rupture, sponsored by Acibadem University. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-06-26.

Sponsored by Acibadem University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 43 studies in Anterior Cruciate Ligament Injuries with a site in Turkey — 18 open to participants now, 19 under way, none of them phase 3. Anterior Cruciate Ligament Injuries · Turkey.

Planned enrollment
8th of 27
60 · median 40
Started
2026
with 8 others
No phase
27 of 43
9 open now
Primary completion
2027-05
later than 14 of 18 live
Registered
38th of 43
by date
Lead sponsor
3 of 43
Acibadem University

Among the 43 studies in Anterior Cruciate Ligament Injuries with a site in Turkey, this one is the 8th largest by planned enrollment of the 27 interventional ones that give a count, is one of 9 that started in 2026, is one of 27 with no phase, reaches primary completion later than 14 of the 18 other live ones, and was the 38th registered.

Anterior Cruciate Ligament Injuries

627 studies on the registry are indexed under Anterior Cruciate Ligament Injuries; 193 are open to participants now.

Browse Anterior Cruciate Ligament Injuries studies →

Open to participants now

18 of the 43 studies in Anterior Cruciate Ligament Injuries with a site in Turkey are open now. Recruiting first, the newest first:

12 more — sign in →

All 18 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 122 Anterior Cruciate Ligament Injuries studies recruiting now, 27 (22%) set no upper age limit and 92 (75%) stop at 75 or younger; 46 take children under 18; 21 take healthy volunteers.

This study: 18 Years to 50 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies in Anterior Cruciate Ligament Injuries with a site in Turkey, or all of them as a file.
02

Study summary

This prospective randomized clinical trial aims to compare quadriceps tendon and peroneus longus tendon autografts in anterior cruciate ligament reconstruction. Patients with anterior cruciate ligament injury undergoing primary reconstruction surgery will be randomly assigned to one of the two graft groups. Clinical examination findings, return-to-sport outcomes, ankle muscle strength, ankle-related functional scores, and gait analysis parameters will be evaluated at 6 months and 12 months postoperatively. The study aims to investigate both knee-related functional outcomes and donor site morbidity associated with graft harvesting techniques.

Read the detailed description

Anterior cruciate ligament (ACL) reconstruction is one of the most commonly performed orthopedic procedures for restoring knee stability and enabling return to sports activities after ACL injury. Various autograft options have been described for ACL reconstruction, including hamstring tendon, bone-patellar tendon-bone, quadriceps tendon, and more recently, peroneus longus tendon grafts. Each graft option has unique biomechanical characteristics, advantages, and potential donor site morbidities.

Quadriceps tendon autografts have gained increasing popularity because of their adequate graft diameter, favorable biomechanical properties, and relatively low donor site complications. Peroneus longus tendon autografts have also emerged as a promising alternative graft source with satisfactory clinical outcomes and sufficient graft size. However, concerns remain regarding donor site morbidity, particularly potential effects on ankle muscle strength and ankle function following peroneus longus tendon harvesting.

This prospective randomized study aims to compare quadriceps tendon and peroneus longus tendon autografts in patients undergoing primary ACL reconstruction. Patients will be randomly assigned into two groups according to graft type. Clinical evaluations, functional knee scores, return-to-sport outcomes, ankle muscle strength assessments, ankle-related functional scores, and gait analysis parameters will be assessed during postoperative follow-up.

Follow-up evaluations will be performed at 6 months and 12 months after surgery. The findings of this study are expected to contribute to graft selection strategies in ACL reconstruction by providing comparative data regarding clinical outcomes, functional recovery, gait characteristics, and donor site morbidity.

03

Conditions studied

  • Anterior Cruciate Ligament Injury
  • Anterior Cruciate Ligament Rupture

Keywords

  • ACL reconstruction
  • Anterior cruciate ligament
  • Quadriceps tendon autograft
  • Peroneus longus tendon autograft
  • Gait analysis
  • Return to sport
  • Knee stability
  • Ankle muscle strength
  • Functional outcomes
  • Randomized controlled trial
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients diagnosed with anterior cruciate ligament rupture
  • Patients scheduled for primary anterior cruciate ligament reconstruction
  • Age between 18 and 50 years
  • Ability to provide
  • Willingness to comply with postoperative rehabilitation and follow-up evaluations

Exclusion criteria

Exclusion Criteria:

  • Previous ligament reconstruction surgery on the affected knee
  • Multi-ligament knee injuries requiring additional ligament reconstruction
  • Severe osteoarthritis of the knee
  • Revision anterior cruciate ligament reconstruction
  • Neuromuscular disorders affecting lower extremity function
  • Active infection
  • Inability to comply with follow-up protocol
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Quadriceps Tendon Autograft

    Patients undergoing anterior cruciate ligament reconstruction using quadriceps tendon autograft.

    Procedure: Anterior Cruciate Ligament Reconstruction Using Quadriceps Tendon Autograft

  • Experimental
    Peroneus Longus Tendon Autograft

    Patients undergoing anterior cruciate ligament reconstruction using peroneus longus tendon autograft.

    Procedure: Anterior Cruciate Ligament Reconstruction Using Peroneus Longus Tendon Autograft

Interventions

  • ProcedureAnterior Cruciate Ligament Reconstruction Using Quadriceps Tendon Autograft

    Anterior cruciate ligament reconstruction performed using quadriceps tendon autograft.

  • ProcedureAnterior Cruciate Ligament Reconstruction Using Peroneus Longus Tendon Autograft

    Anterior cruciate ligament reconstruction performed using peroneus longus tendon autograft.

06

What researchers measure

Primary outcomes

  1. International Knee Documentation Committee (IKDC) Subjective Knee Score

    Comparison of postoperative subjective knee function between quadriceps tendon and peroneus longus tendon autograft groups using the International Knee Documentation Committee (IKDC) subjective knee evaluation form.

    Time frame: 12 months postoperatively

Secondary outcomes

  1. Return to Sport Rate

    6 and 12 months postoperatively

    Time frame: Assessment of return to pre-injury level of sports activity following anterior cruciate ligament reconstruction.

  2. Ankle Plantar Flexion Strength

    Isokinetic ankle plantar flexion strength will be evaluated using an isokinetic dynamometer. Peak torque (Nm) during plantar flexion will be recorded and compared between study groups.

    Time frame: 6 and 12 months postoperatively

  3. Ankle Dorsiflexion Strength

    Isokinetic ankle dorsiflexion strength will be evaluated using an isokinetic dynamometer. Peak torque (Nm) during dorsiflexion will be recorded and compared between study groups.

    Time frame: 6 and 12 months postoperatively

  4. Ankle Inversion Strength

    Isokinetic ankle inversion strength will be evaluated using an isokinetic dynamometer. Peak torque (Nm) during inversion will be recorded and compared between study groups.

    Time frame: 6 and 12 months postoperatively

  5. Ankle Eversion Strength

    Isokinetic ankle eversion strength will be evaluated using an isokinetic dynamometer. Peak torque (Nm) during eversion will be recorded and compared between study groups.

    Time frame: 6 and 12 months postoperatively

  6. Ankle Rotational Strength

    Isokinetic ankle rotational strength will be evaluated using an isokinetic dynamometer. Peak torque (Nm) during rotational movements will be recorded and compared between study groups.

    Time frame: 6 and 12 months postoperatively

  7. Ground Reaction Force

    Lower extremity biomechanical performance will be assessed using the VALD ForceDecks dual force plate system. Ground reaction force (N) during standardized standing and functional testing tasks will be recorded and compared between study groups.

    Time frame: 6 and 12 months postoperatively

  8. Force Asymmetry

    Lower extremity biomechanical performance will be assessed using the VALD ForceDecks dual force plate system. Force asymmetry (%) during standardized standing and functional testing tasks will be recorded and compared between study groups.

    Time frame: 6 and 12 months postoperatively

  9. Weight Distribution

    Lower extremity biomechanical performance will be assessed using the VALD ForceDecks dual force plate system. Weight distribution (%) during standardized standing and functional testing tasks will be recorded and compared between study groups.

    Time frame: 6 and 12 months postoperatively

07

Study locations

1 of 1 sites recruiting
  • Acibadem Fulya Hospital, Sport Medicine Center
    Istanbul, Besiktas 34349, Turkey (Türkiye)
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for May 2027, 12 months after the start.

Of 279 non-industry interventional studies with no phase under Anterior Cruciate Ligament Injuries, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 70. This study's planned 12 months is below that.

Counting every sponsor, half of 288 studies reached it within 30 months; a quarter within 14 and three quarters within 70.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 12, 2026
First posted
Jun 26, 2026
StartActual
May 1, 2026
Primary completionEst.
May 2027
CompletionEst.
Dec 2027
Last update
Jun 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07671729
Responsible party
Muzaffer Agir (Orthopaedic Surgeon, Department of Orthopaedics and Traumatology, Acibadem University) — Principal investigator
First posted
Jun 26, 2026
Start date
May 1, 2026
Primary completion
May 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Jun 26, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion